Sort
1,049,261 grants matching “t cell”
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease
$9,592,233Gary E Gibson · Winifred Masterson Burke Med Res Inst · R01 · FY2025 · AG
A platform for cell type-level transcriptomic, epigenomic and spatial interrogation of Alzheimer's disease
$9,590,782Ed Lein · Allen Institute · U19 · FY2022 · AG
HEAL: Development of Clinical Candidate Drugs for Pain, Addiction and Overdose
$9,587,227Donald Lo · National Center For Advancing Translational Sciences · ZIA · FY2019 · TR
University of New Mexico Center for Molecular Discovery (ARRA G20)
$9,586,673Paul B Roth · University Of New Mexico Health Scis Ctr · G20 · FY2010 · RR
NeuroNex Technology Hub: Miniaturized open source devices for calcium imaging, electrophysiology, and real-time control of neural activity
$9,582,530Peyman Golshani · University Of California-Los Angeles · · FY2017 · BIO
DCTD Biopharmaceutical Development
$9,577,323David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2012 · CA
Clinical Islet Transplantation: Data Coordinating Center
$9,573,329University Of Iowa · U01 · FY2004 · DK
Helping to End Addiction Long-term (HEAL): Development of Clinical Candidate Drugs for Pain, Addiction and Overdose
$9,556,745Donald Lo · National Center For Advancing Translational Sciences · ZIA · FY2021 · TR
A platform for cell type-level transcriptomic, epigenomic and spatial interrogation of Alzheimer's disease
$9,555,451Ed Lein · Allen Institute · U19 · FY2023 · AG
NEXT GENERATION MULTI-USE HEAVY-DUTY HIGH-FLOW DIRECT-FILL HYDROGEN REFUELING STATION WITH STANDARDIZED DESIGN THE GOAL OF THIS FOA PROJECT IS TO DESIGN, DEVELOP, BUILD, INSTALL, AND DEMONSTRATE AN ADVANCED NEXT GENERATION MULTI-USE (GH2 H70/H70HF AND SLH2) DIRECT FILL (MUDF) H2 STATION. THIS WILL ENABLE THE MARKET FOR MD/HD FUEL CELL TRUCKS TO BE COMMERCIALLY VIABLE SIMULTANEOUSLY, ACCOMMODATING LD FUEL CELL VEHICLES. COMMERCIALLY VIABLE INDICATES THAT; H2 CAN BE SOLD AT A PRICE WHERE OWNERSHIP AND OPERATION OF H2 STATIONS AND OWNERSHIP AND OPERATION OF LD/MD/HD VEHICLES ARE BOTH PROFITABLE. THE OBJECTIVES OF THIS FOA PROJECT ARE DELINEATED BELOW BY THE FOUR BUDGET PERIODS. BUDGET PERIOD 1: COMPONENT AND CONTROLS DESIGN: THE OBJECTIVE IN THIS PHASE IS TO USE THE NREL DYNAMIC SIMULATION MODEL AND TEA MODEL TO INFORM AND OPTIMIZE THE SYSTEM DESIGN. THE SYSTEM COMPONENTS AND CONTROLS WILL BE DESIGNED ON PAPER BASED ON THE PERFORMANCE CRITERIA ESTABLISHED BY THE PROJECT TEAM AND THROUGH MODELING. IN THE FIRST YEAR, THE TEAM WILL ALSO CONDUCT PRELIMINARY FUELING TESTING ON THE PROTOTYPE UNIT IN LIVERMORE CALIFORNIA. LATER IN THE YEAR, THE FIRST PRE-COMMERCIAL UNIT WILL BE INSTALLED AT THE PORT OF OAKLAND HD STATION FOR REAL WORLD LIMITED TESTING. BUDGET PERIOD 2: COMPONENT BUILD AND TEST: AFTER DESIGN AND PRELIMINARY TESTING ON THE PROTOTYPE AND PRE-COMMERCIAL UNIT IS COMPLETED, THE COMPONENTS WILL BE BUILT TO SPECIFICATION. KEY COMPONENTS WILL THEN BE TESTED TO ENSURE THEY OPERATE AS INTENDED AND MEET PERFORMANCE REQUIREMENTS. IN THE SECOND YEAR, PERMITTING AND DESIGN FOR SITE PREPARATION WILL INITIALIZE. BUDGET PERIOD 3: SITE PREPARATION / INSTALLATION / COMMISSIONING AND STATION OPERATION: THE OBJECTIVE IN THIS PHASE IS TO CONDUCT FINAL COMMERCIAL SITE PREPARATION, INSTALLATION, AND COMMISSIONING OF THE MUDF H2 STATION EQUIPMENT, AND TO QUANTIFY COST AND TIME REDUCTIONS IN COMPARISON TO GEN 4 STATION. THE GH2 H70 DISPENSERS WILL BE VALIDATED TO APPLICABLE STANDARDS TO ENSURE THE J2601/5 FUELING PROTOCOL IS IMPLEMENTED CORRECTLY, AND THE MUDF H2 STATION WILL BE EVALUATED AGAINST THE FUELING PERFORMANCE OBJECTIVES. BUDGET PERIOD 4: STATION OPERATION: THE OBJECTIVES IN THIS PHASE ARE TO PROVE THE PERFORMANCE REQUIREMENTS AND OBJECTIVES FOR THE MUDF H2 STATION CAN BE MET UNDER REAL WORLD OPERATION BY COLLECTING, ANALYZING, AND QUANTIFYING THE REAL-WORLD OPERATIONAL AND FUELING DATA AGAINST THE METRICS. THE EXPECTED OUTCOME OF THIS PHASE IS THE PUBLICATION OF A COMPREHENSIVE REFERENCE STATION DESIGN AND THE PUBLICATION OF THE EXPANDED AND ENHANCED NREL H2FILLS AND TEA MODELS.
$9,550,000Firstelement Fuel Inc. · · FY2025 · Department of Energy
Phase I HIV vaccine trial with DNAALVAC-HIV gp120 delta V1 vaccines
$9,534,502Genoveffa Franchini · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Einstein Stem Cell Research Institute
$9,532,509Allen M. Spiegel · Albert Einstein College Of Medicine · C06 · FY2010 · RR
B Cell Epitope Mapping of Viral and Parasitic Antigens
$9,527,052Daved Fremont · Washington University · N01 · FY2014 · AI
DCTD Biopharmaceutical Development
$9,525,000Larry Arthur · Leidos Biomedical Research, Inc. · N01 · FY2010 · CA
Inter- and Intra-Species Comparative Sequencing
$9,523,646James Thomas · National Human Genome Research Institute · ZIB · FY2024 · HG
Rutgers University Cell and DNA Repository Renovation
$9,492,078Jay Arnold Tischfield · Rutgers, The State Univ Of N.J. · C06 · FY2010 · RR
FY19 FACILITIES TO B
$9,486,322Adam Leaman · Leidos Biomedical Research, Inc. · N01 · FY2019 · CA
STUDIES TO EVALUATE THE TOXIC AND CARCINOGENIC POTENTIAL OF CELL PHONE RADIATION
$9,475,212Dave McCormick · Iit Research Institute · N01 · FY2011 · ES
Consortia for Innovative AIDS Research in Nonhuman Primates
$9,472,469Dan H. Barouch · Beth Israel Deaconess Medical Center · UM1 · FY2018 · AI
Infectious Diseases Research Technologies Core - Bethesda
$9,451,765Robert Hohman · National Institute Of Allergy And Infectious Diseases · ZIC · FY2011 · AI
CCR Dedicated Cores
$9,446,458Robin Winkler Pickett · Division Of Basic Sciences - Nci · ZIC · FY2022 · CA
Gynecologic Oncology Group
$9,434,066Philip J Disaia · Gynecologic Oncology Group · U10 · FY2011 · CA
Center for Genomic Studies on Mental Disorders
$9,428,183Jay Arnold Tischfield · Rutgers, The State Univ Of N.J. · U24 · FY2015 · MH
Center for Alzheimer's and Related Dementias (CARD): iPSC Neurodegenerative Diseases Initiative
$9,416,906Andrew Singleton · National Institute On Aging · ZIA · FY2022 · AG
Institute of Translational Health Sciences
$9,405,183Mary L. Disis · University Of Washington · UL1 · FY2017 · TR